Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Adv Hematol Oncol. 2023 Feb;21(2):68-75.
Before the development of tyrosine kinase inhibitors (TKIs), the outcome of patients with a diagnosis of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia was dismal. Combinations of TKIs and chemotherapy improved survival rates, but allogeneic stem cell transplant was still relied on to avoid relapse in most cases. More recently, the chemotherapy-free combination of blinatumomab plus newer-generation TKIs has shown favorable results and may eliminate the need for allogeneic stem cell transplant. This review discusses the evolution of the treatment of Ph-positive acute lymphoblastic leukemia with chemotherapy-free regimens in the current era.
在酪氨酸激酶抑制剂 (TKI) 发展之前，费城染色体 (Ph) 阳性急性淋巴细胞白血病患者的预后很差。TKI 与化疗的联合应用改善了生存率，但在大多数情况下，异体干细胞移植仍然是避免复发的手段。最近，无化疗联合blinatumomab 与新一代 TKI 的方案显示出良好的结果，可能消除异体干细胞移植的需求。本文综述了当前时代无化疗方案治疗 Ph 阳性急性淋巴细胞白血病的演变。
